Contemporary therapeutic approaches targeting bone complications in prostate cancer.

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.

Metastasis and bone loss: advancing treatment and prevention.

Electronic effects in iridium C-H borylations: insights from unencumbered substrates and variation of boryl ligand substituents.

Equine embryonic stem-like cells and mesenchymal stromal cells have different survival rates and migration patterns following their injection into damaged superficial digital flexor tendon.

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Novel bone-targeted strategies in oncology.

An endogenous F-box protein regulates ARGONAUTE1 in Arabidopsis thaliana.

Gastric mucosa-associated lymphoid tissue lymphoma.

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.